**A. grandis >25** and measuring the size of larval parasites (3). Recently, PCR has been used for diagnosis in veterinary infections (2,7).

For the patient in our study, molecular analysis identified human pentastomiasis by using a formalin-fixed microscope slide that had been stored for 7 years. A difference of 2 nt each was seen when the amplified nucleotide sequence was compared with database sequences of *A. agkistrodonis* and *A. moniliformis*. However, there is no database entry in GenBank for *A. grandis*, the geographically closest *Armillifer* species. Serologic assays have been developed for identification of *A. armillatus* (2), but no serum was available for retrospective analysis. In special settings, such as tropical snake farming and pet keeping, pentastomiasis may be a public health concern (2). However, most infections have been linked to consumption of undercooked snake meat or other snake products (1).

Most immigrants who were given a diagnosis of visceral pentastomiasis were from Nigeria or the Congo region, and diagnoses were made after death. Molecular analysis is particularly valuable when only autopic paraffin-embedded patient material is available. For industrialized countries, where experience in morphologic identification of unusual parasite species is limited, molecular analysis is a valuable diagnostic tool. Our case-patient constitutes a record of imported *Armillifer* species pentastomiasis to Germany. Because of increasing international migration, more cases of pentastomiasis are likely to be seen.

**Dennis Tappe,**
**Alexandra Haeupler,**
**Hansjörg Schäfer,** **Paul Racz,**
**Jakob P. Cramer,**
**and Sven Poppert**

Author affiliations: University of Würzburg, Würzburg, Germany (D. Tappe); Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany (A. Haeupler, P. Racz, S. Poppert); and University Medical Center Hamburg–Eppendorf, Hamburg (H. Schäfer, J.P. Cramer)

**Mycobacterium kyorinense Infection**

To the Editor: Mycobacterium *kyorinense* is a nonpigmented, slowly growing mycobacterium that was initially isolated in 2007 from a patient with pneumonia in Japan (1,2). The sequences of the 16S rRNA, hsp65, and rpoB genes of *M. kyorinense* were closely related to, but different from, those of the type strains of *M. celatum* and *M. branderi*, the 2 most phylogenetically related species (1). Biochemical tests, such as those for arylsulfatase activity, tellurite reduction, and heat-stable catalase, also distinguish *M. kyorinense* from *M. celatum* and *M. branderi*. In our initial report, in which this species was first recognized, we described 3 strains isolated from Japanese patients (1). Recently, 1 additional case was reported in Brazil (3). Here we describe 7 newly identified patients whose infection may have been caused by *M. kyorinense*.

In reviewing the characteristics of these 11 patients (10 from Japan and 1 from Brazil), we found no apparent contacts among them. Nine of the 11 patients had respiratory infections, 1 had lymphadenitis, and 1 had arthritis (Table). Of these, 9 patients fulfilled the criteria for infections of clinical significance (4) and were considered to harbor infection by *M. kyorinense*. Of the 9 patients with respiratory infections, 4 died as a result of the infection. These data suggest that *M. kyorinense* belongs to a class of nontuberculous mycobacteria that are pathogenic for humans and have substantial clinical effects.

Among the 10 patients for whom precise clinical records were available, 7 patients were treated with first-line tuberculosis drugs, mainly rifampin, isoniazid, and ethambutol, but these therapies were ineffective for all patients.

References


Address for correspondence: Dennis Tappe, Institute of Hygiene and Microbiology, University of Würzburg, Josef-Schneider-Str 2, 97080 Würzburg, Germany; email: dtappe@hygiene.uni-wuerzburg.de

DOI: http://dx.doi.org/10.3201/eid1903.121508
Six patients received a combination of antimicrobial drugs, including macrolides and fluoroquinolones, as first- or second-line chemotherapy, and infection was subdued without recurrence in 5 patients. In contrast, 4 patients with pneumonia who did not receive sufficient therapy with the latter regimen eventually died of infection (3 patients) or breast cancer (1 patient).

MICs of various antimicrobial drugs for the 9 strains of *M. kyorinense* were determined by the broth microdilution method as described (1). For most strains, the MICs of rifampin, ethambutol, and isoniazid were relatively high, and MICs of macrodiloids, aminoglycosides, and quinolones were relatively low. Notably, MICs of rifampin were remarkably high (>32 μg/mL) for all tested strains (Table).

Direct sequencing of the 16S rRNA gene, performed as previously described, revealed that 8 of the 9 available *M. kyorinense* isolates were identical across the entire sequenced interval (1,470 bp). The sole exception was the strain from Brazil, which showed a 4-bp substitution that the other strains did not (3). Although the other 8 strains had identical 16S rRNA sequences, all showed heterogeneity at 9 positions that had not been observed to be heterogeneous in the previous investigation (7). This observation might reflect the presence of 2 copies of the 16S rRNA gene, as has been occasionally reported for other mycobacterial species, including *M. celatum* (5). Direct sequencing of the entire *rpoB* gene demonstrated that all strains had identical sequences for this locus. The strains differed from the sequence of *M. tuberculosis* at 15 nt within codons 511–533. At the amino acid level, these changes were synonymous for the 2 species, with the exception of amino acid residue 531. This residue, Ser531 in the *M. tuberculosis* RpoB protein, was replaced by an Asp in *M.*

---

### Table: Clinical characteristics of patients infected with *Mycobacterium kyorinense* and antimicrobial susceptibility of the organism

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1†</th>
<th>2†</th>
<th>3‡</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>89</td>
<td>64</td>
<td>70</td>
<td>81</td>
<td>50</td>
<td>67</td>
<td>72</td>
<td>48</td>
<td>66</td>
<td>60</td>
<td>26</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Major infection site</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
<td>Lymph node</td>
<td>Lung</td>
<td>Lung</td>
<td>Joint</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
</tr>
<tr>
<td>Specimen Coexisting disease</td>
<td>Sputum</td>
<td>COPD</td>
<td>Sputum</td>
<td>COPD</td>
<td>Sputum</td>
<td>None</td>
<td>BAL</td>
<td>None</td>
<td>Sputum</td>
<td>None</td>
<td>Sputum</td>
</tr>
<tr>
<td>Country</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
<td>Japan</td>
</tr>
<tr>
<td>AM drug MIC, μg/mL</td>
<td>STR 0.25</td>
<td>0.25</td>
<td>0.25</td>
<td>S</td>
<td>ND</td>
<td>0.25</td>
<td>0.125</td>
<td>0.5</td>
<td>0.25</td>
<td>0.5</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>EMB 4</td>
<td>4</td>
<td>2</td>
<td>R</td>
<td>128</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>KAN 0.5</td>
<td>1</td>
<td>0.25</td>
<td>S</td>
<td>ND</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>INH 16</td>
<td>16</td>
<td>32</td>
<td>R</td>
<td>2</td>
<td>0.5</td>
<td>8</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>R</td>
</tr>
<tr>
<td></td>
<td>Rif 32</td>
<td>32</td>
<td>32</td>
<td>R</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>32</td>
<td>R</td>
</tr>
<tr>
<td></td>
<td>LVX 0.125</td>
<td>0.125</td>
<td>0.03</td>
<td>R</td>
<td>0.25</td>
<td>0.06</td>
<td>0.06</td>
<td>0.125</td>
<td>0.125</td>
<td>0.25</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>CLR 0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>ND</td>
<td>0.03</td>
<td>0.03</td>
<td>ND</td>
<td>0.03</td>
<td>0.125</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>AMK 0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>ND</td>
<td>0.5</td>
<td>1</td>
<td>ND</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>S</td>
</tr>
</tbody>
</table>

#### Clinical efficacy of AM drug combination

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Dead</th>
<th>Dead</th>
<th>Dead</th>
<th>Dead</th>
<th>Alive</th>
<th>Alive</th>
<th>Alive</th>
<th>Alive</th>
<th>Alive</th>
<th>Alive</th>
<th>Dead</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIP</td>
<td>None</td>
<td>None</td>
<td>RFB, INH, EMB, CLR, RIF</td>
<td>None</td>
<td>RFB, INH, EMB, CLR, RIF</td>
<td>None</td>
<td>RFB, INH, EMB, CLR, RIF</td>
<td>None</td>
<td>RFB, INH, EMB, CLR, RIF</td>
<td>None</td>
<td>RFB, INH, EMB, CLR, RIF</td>
</tr>
<tr>
<td>LVX</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

---

†Reported in (1,2). ‡Reported in (1). §Reported in (3).
kyorinense. Notably, Ser531 is the most frequent location of substitutions in rifampin-resistant strains of M. tuberculosis (6).

Why M. kyorinense has been isolated almost exclusively in Japan is not clear. This tendency may be largely caused by a reporting bias in Japan. However, M. kyorinense may have a particular geographic distribution. In this context, it is noteworthy that the sole strain from Brazil characterized in the current study differed slightly in 16S rRNA sequences from the strains isolated in Japan.

It also is notable that the M. kyorinense strains isolated so far were invariably resistant to rifampin by in vitro susceptibility testing. Rifampin appeared to have been clinically ineffective in most patients, although definite efficacy of antimicrobial drugs cannot be evaluated by this retrospective type of study. Analysis of the rpoB gene sequence of M. kyorinense revealed the replacement of aa 531 when compared to the rpoB gene sequence of the M. tuberculosis protein. This finding suggests that M. kyorinense is inherently resistant to rifampin because of the structural features of its RpoB protein. Amino acid replacement at RpoB residue 531 also has been reported in other bacterial species resistant to rifampin, such as M. celatum, Borrelia burgdorferi, and Spiroplasma citri (7–9). In any case, understanding the intrinsic resistance of M. kyorinense to rifampin is critical for appropriately treating infection by this microorganism. On the basis of the results of our study, we recommend that a combination of fluoroquinolones and macrolides and/or aminoglycosides be used for the initial treatment of infection by M. kyorinense in most patients.

Acknowledgments

We thank KiyoYumi Ohkusu for his contribution in identifying M. kyorinense isolates from patient 5.

This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

The 16S rRNA and rpoB sequences of the M. kyorinense type strain KUM 060204 were deposited in GenBank with accession numbers AB370111 and JQ744020, respectively. The variant 16S rRNA sequences of M. kyorinense strains isolated from case-patients nos. 9 (KUM060200) and 11 (HF1629) were deposited as JN634643 and JQ717033, respectively.

Hiroaki Ohnishi, Shota Yonetani, Satsuki Matsuhashi, Hiroo Wada, Kei Takeshita, Daisuke Kuramochi, Paulo Cesar de Souza Caldas, Carlos Eduardo Dias Campos, Bianca Porphirio da Costa, Jesus Pais Ramos, Shinichirou Mikura, Eriko Narisawa, Akira Fujita, Yasunori Funayama, Yoshihiro Kobashi, Yumi Sakakibara, Yukako Ishiyama, Shunji Takakura, Hajime Goto, and Takashi Watanabe

Author affiliations: Kyorin University School of Medicine, Tokyo, Japan (H. Ohnishi, S. Yonetani, S. Matsuhashi, H. Wada, H. Goto, Y. Ishiyama, T. Watanabe); Kitasato University–Kitasato Institute Hospital, Tokyo (K. Takeshita); International University of Health and Welfare Hospital, Tochigi, Japan (D. Kuramochi); Centro de Referencia Prof. Helio Fraga, Rio De Janeiro, Brazil (P.C.d.S Caldas, C.E.D. Campos, B.P. da Costa, J.P. Ramos); Tokyo Metropolitan Tama Medical Center, Tokyo (S. Mikura, E. Narisawa, A. Fujita); Tsukuba Gakuen Hospital, Ibaraki, Japan (Y. Funayama); Kawasaki Medical School, Okayama, Japan (Y. Kobashi); Toshiba Hospital, Tokyo (Y. Sakakibara); and Kyoto University Graduate School of Medicine, Kyoto, Japan (S. Takakura)

DOI: http://dx.doi.org/10.3201/eid1903.120591

References


Address for correspondence: Hiroaki Ohnishi, Department of Laboratory Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan; email: onishi@ks.kyorin-u.ac.jp